PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN'S DISEASE

Anti-TNF drugs are a fundamental part of the treatment of Crohn's disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Identify potential factors related to loss of response to anti-TNF agents in Crohn's disease patients. This is a p...

Full description

Saved in:
Bibliographic Details
Published inArquivos brasileiros de cirurgia digestiva : ABCD Vol. 33; no. 2; p. e1522
Main Authors Santos, Byanca Rossetti Moreira Dos, Santos, Carlos Henrique Marques Dos, Santos, Vitória Rossetti Moreira Dos, Torrez, Claudia Yanina Garcia, Palomares-Junior, Daniel
Format Journal Article
LanguageEnglish
Published Brazil Colégio Brasileiro de Cirurgia Digestiva 01.01.2020
Subjects
Adalimumab
Adolescent
Adult
Crohn disease
Crohn Disease - drug therapy
Crohn Disease - surgery
Drug Tolerance
Female
Humans
Infliximab
Infliximab - therapeutic use
Male
Middle Aged
Original
Prospective Studies
Treatment Failure
Treatment Outcome
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor Necrosis Factor-alpha
Young Adult
Online AccessGet full text

Cover

More Information
Summary:Anti-TNF drugs are a fundamental part of the treatment of Crohn's disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Identify potential factors related to loss of response to anti-TNF agents in Crohn's disease patients. This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05. Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Anemia and prior CD surgery have been linked to loss of anti-TNF response.
Bibliography:Conflict of interest: none
ISSN:0102-6720
2317-6326
DOI:10.1590/0102-672020200002e1522